“…Our results showed that, in SLE and LN, serum CRP levels did not correlate with disease progression. The inability of CRP to reflect inflammatory activity in SLE could be explained by IFN1 gene overexpression or dysregulation, inhibitory effects of IFN1 IL-6/IL-1beta-induced CRP gene transcription, CRP’s proinflammatory/anti-inflammatory contradictory effects, the existence of several conformational isoforms, the presence of anti-CRP antibodies, polymorphisms (such as rs1205) in the CRP gene, multiple locations of protein synthesis (hepatocytes, kidney cells, neural cells, respiratory epithelial cells, adipocytes, leukocytes), and local conditions (acid microenvironment, NO release, IFN activation, proinflammatory cytokines, urea, heat, inflamed tissue, calcium, phospholipase A2, transcriptional activation of STAT3, C/EBP and NF-kB) [ 2 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 ]. Many published reports investigating CRP as a biological response modifier in IFN-dependent conditions have shown that monomeric anti-CRP antibodies are associated with increased frequency and stimulation of IL-6 and TNF alpha production in LN [ 27 ].…”